Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study.

Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, Alonso J, Nabutovsky Y, Neason C.

J Cardiovasc Electrophysiol. 2014 Jan;25(1):52-9. doi: 10.1111/jce.12273. Epub 2013 Sep 24.

PMID:
24112717
2.

Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.

Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV.

Circ Arrhythm Electrophysiol. 2014 Feb;7(1):164-70. doi: 10.1161/CIRCEP.113.001217. Epub 2014 Jan 20. Review.

3.

Rationale and design for programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock (PROVIDE) study.

Saeed M, Razavi M, Neason CG, Petrutiu S.

Europace. 2011 Nov;13(11):1648-52. doi: 10.1093/europace/eur195. Epub 2011 Jul 21.

PMID:
21784746
4.

Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial.

Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A.

JAMA. 2013 May 8;309(18):1903-11. doi: 10.1001/jama.2013.4598. Erratum in: JAMA. 2013 Jun 26;309(24):2552.

PMID:
23652522
5.

Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK; PREPARE Study Investigators.

J Am Coll Cardiol. 2008 Aug 12;52(7):541-50. doi: 10.1016/j.jacc.2008.05.011.

6.

Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.

Buber J, Luria D, Gurevitz O, Bar-Lev D, Eldar M, Glikson M.

Europace. 2014 Feb;16(2):227-34. doi: 10.1093/europace/eut302. Epub 2013 Oct 9.

PMID:
24108231
7.

Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.

Kloppe A, Proclemer A, Arenal A, Lunati M, Martìnez Ferrer JB, Hersi A, Gulaj M, Wijffels MC, Santi E, Manotta L, Mangoni L, Gasparini M.

Circulation. 2014 Jul 22;130(4):308-14. doi: 10.1161/CIRCULATIONAHA.114.009468. Epub 2014 May 16.

8.

Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks.

Silver MT, Sterns LD, Piccini JP, Joung B, Ching CK, Pickett RA, Rabinovich R, Liu S, Peterson BJ, Lexcen DR; Shock-Less Investigators.

Heart Rhythm. 2015 Mar;12(3):545-53. doi: 10.1016/j.hrthm.2014.11.002. Epub 2014 Nov 7.

PMID:
25460168
9.

Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.

Powell BD, Saxon LA, Boehmer JP, Day JD, Gilliam FR 3rd, Heidenreich PA, Jones PW, Rousseau MJ, Hayes DL.

J Am Coll Cardiol. 2013 Oct 29;62(18):1674-9. doi: 10.1016/j.jacc.2013.04.083. Epub 2013 Jun 27.

10.
11.

Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.

Fröhlich GM, Holzmeister J, Hübler M, Hübler S, Wolfrum M, Enseleit F, Seifert B, Hürlimann D, Lehmkuhl HB, Noll G, Steffel J, Falk V, Lüscher TF, Hetzer R, Ruschitzka F.

Heart. 2013 Aug;99(16):1158-65. doi: 10.1136/heartjnl-2013-304185. Epub 2013 Jun 27.

PMID:
23813845
12.

Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.

Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R, Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK, Krahn AD, Wolfe LG, Feinstein S, Ellenbogen KA.

Europace. 2013 Mar;15(3):347-54. doi: 10.1093/europace/eus316. Epub 2012 Sep 21.

PMID:
23002195
13.

Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.

Hayashi T, Fukamizu S, Hojo R, Komiyama K, Tanabe Y, Tejima T, Soejima K, Nishizaki M, Hiraoka M, Ako J, Momomura S, Sakurada H.

Europace. 2013 Oct;15(10):1507-15. doi: 10.1093/europace/eut050. Epub 2013 Apr 19.

PMID:
23603305
14.

Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study.

Friedman PA, McClelland RL, Bamlet WR, Acosta H, Kessler D, Munger TM, Kavesh NG, Wood M, Daoud E, Massumi A, Schuger C, Shorofsky S, Wilkoff B, Glikson M.

Circulation. 2006 Jun 27;113(25):2871-9. Epub 2006 Jun 12.

15.

Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.

Barbosa MP, da Costa Rocha MO, de Oliveira AB, Lombardi F, Ribeiro AL.

Europace. 2013 Jul;15(7):957-62. doi: 10.1093/europace/eut011. Epub 2013 Feb 1. Erratum in: Europace. 2013 Nov;15(11):1684.

PMID:
23376978
16.

A prospective randomized trial of single- or dual-chamber implantable cardioverter-defibrillators to minimize inappropriate shock risk in primary sudden cardiac death prevention.

Friedman PA, Bradley D, Koestler C, Slusser J, Hodge D, Bailey K, Kusumoto F, Munger TM, Militanu A, Glikson M.

Europace. 2014 Oct;16(10):1460-8. doi: 10.1093/europace/euu022. Epub 2014 Jun 13.

PMID:
24928948
17.

Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study.

Proclemer A, Muser D, Campana A, Zoni-Berisso M, Zecchin M, Locatelli A, Brieda M, Gramegna L, Santarone M, Chiodi L, Mazzone P, Rebellato L, Facchin D.

Int J Cardiol. 2013 Sep 30;168(2):1416-21. doi: 10.1016/j.ijcard.2012.12.042. Epub 2012 Dec 31.

PMID:
23287697
18.

Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).

Cheng A, Zhang Y, Blasco-Colmenares E, Dalal D, Butcher B, Norgard S, Eldadah Z, Ellenbogen KA, Dickfeld T, Spragg DD, Marine JE, Guallar E, Tomaselli GF.

Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1084-91. doi: 10.1161/CIRCEP.113.001705. Epub 2014 Oct 1.

19.

Programming antitachycardia pacing for primary prevention in patients with implantable cardioverter defibrillators: results from the PROVE trial.

Saeed M, Neason CG, Razavi M, Chandiramani S, Alonso J, Natarajan S, Ip JH, Peress DF, Ramadas S, Massumi A.

J Cardiovasc Electrophysiol. 2010 Dec;21(12):1349-54. doi: 10.1111/j.1540-8167.2010.01825.x.

PMID:
20561107
20.

Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.

Chan PS, Nallamothu BK, Spertus JA, Masoudi FA, Bartone C, Kereiakes DJ, Chow T.

Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):16-24. doi: 10.1161/CIRCOUTCOMES.108.807123. Epub 2009 Jan 6.

Supplemental Content

Support Center